PROGRAM 3 (IMMUNOLOGY AND CANCER)

计划 3（免疫学和癌症）

• 批准号: 8518668
• 负责人: THOMAS F GAJEWSKI
• 金额: $ 14万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-04-01 至 2013-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8518668
• 关键词: Address; Allogenic; Antibodies; Antigens; Autoimmunity; B-Lymphocytes; Back; Blood; Bone Marrow; Cancer Center Support Grant; Cancer Immunology Science; Cancer Vaccine Related Development; Cancer Vaccines; Cells; Clinic; Clinical; Clinical Research; Clinical Trials; Collaborations; Core Facility; Cross Presentation; Cyclic GMP; Development; Direct Costs; Effector Cell; Environment; Failure; Flow Cytometry; Fostering; Funding; Generations; Goals; Grant; Human; Immune; Immune Tolerance; Immune response; Immune system; Immunohistochemistry; Immunologic Monitoring; Immunologics; Immunology; Immunotherapeutic agent; Immunotherapy; Inflammation; Interferons; Interleukin-2; Investigation; Knowledge; Laboratories; Lymphocyte; Malignant Neoplasms; Memory; Monitor; Monoclonal Antibodies; Mus; Natural Immunity; Pathway interactions; Patients; Peer Review; Pre-Clinical Model; Preparation; Program Research Project Grants; Publications; Regulation; Research; Research Activity; Research Personnel; Roche brand of rituximab; Roche brand of trastuzumab; Role; Secondary to; Services; Signal Transduction; Site; Stem cell transplant; System; T cell differentiation; T cell response; T-Lymphocyte; Therapeutic; Translating; Translational Research; Tumor Antigens; Tumor Immunity; United States National Institutes of Health; University of Chicago Cancer Research Center; antigen processing; base; bench to bedside; clinical application; cytokine; fundamental research; improved; in vivo; insight; member; mouse model; neoplastic cell; novel; programs; response; success; trafficking; tumor; tumor immunology

The Immunology and Cancer Program (Program 3) has been an integral component of the UCCRC for more than 20 years. It has 19 members from 5 departments, and is supported by a total of $7,660,269 in peer-reviewed funding (annual direct costs), with $2,154,936 from the NCI. Over the past grant period, program members have produced a total of 387 peer-reviewed publications, including 11% that were intraprogrammatic and 15% that were interprogrammatic collaborations. It is well established that tumors can express antigens that can be recognized by specific T cells or antibodies. Established immunologic therapies in the clinic include allogeneic bone marrow or blood stem cell transplantation, the monoclonal antibodies Herceptin and Rituxan, and the cytokines IL-2 and IFN-cc. However, as fundamental knowledge of the immune system continues to increase at a rapid pace, the potential for improving upon existing immune-based therapies, as well as for developing new immunotherapeutic approaches, continues to expand. The overall goals of the Immunology and Cancer Program are to foster the best possible research that has relevance for the cancer setting, to support an environment that brings new immunology concepts into preclinical models of anti-tumor immunity, and to translate fundamental discoveries into clinical application. A major accomplishment of the Program is the expansion of the clinical/translational component. These goals are supported by severa key Core Facilities, in particular the Flow Cytometry, Fitch Monoclonal Antibody, Immunohistochemistry, and the Human Immunologic Monitoring Cores. The Immunology and Cancer Program also depends on the services of the cGMP Facility (a UCCRC developing core) for preparation of clinical-grade immunotherapeutic products for clinical administration. By incorporating detailed scientific endpoint monitoring into clinical studies, new key information is being generated that has led to the development of new hypotheses that can then be interrogated back in the basic laboratory. Thus, the Immunology and Cancer Program has evolved into a clear example of bi-directional translational research.

免疫学和癌症计划（计划3）一直是UCCRC不可或缺的组成部分 超过20年。它有来自5个部门的19名成员，并得到了总计7,660,269美元的支持 同行评审的资金（年度直接费用），NCI的$ 2,154,936。在过去的赠款期间， 计划成员总共制作了387个同行评审的出版物，其中包括11％ 磁内图和15％是解释合作的合作。 众所周知，肿瘤可以表达抗原，这些抗原可以被特定的T细胞或 抗体。诊所已建立的免疫疗法包括同种异体骨髓或血液 干细胞移植，单克隆抗体赫赛汀和利图糖，以及细胞因子IL-2和 IFN-CC。但是，随着对免疫系统的基本知识在迅速地增加 步伐，改善现有的免疫疗法的潜力，以及开发新的疗法 免疫治疗方法不断扩大。免疫学和癌症的总体目标 计划是促进与癌症环境有相关性的最佳研究，以支持 将新的免疫学概念带入抗肿瘤免疫模型的环境，并 将基本发现转化为临床应用。该计划的主要成就是 临床/翻译成分的扩展。这些目标得到Severa关键核心的支持 设施，特别是流式细胞仪，惠誉单克隆抗体，免疫组织化学和 人类免疫学监测核心。免疫学和癌症计划也取决于 CGMP设施（UCCRC开发核心）的服务用于准备临床级免疫治疗 临床给药的产品。通过合并详细的科学终点监视 在临床研究中，正在生成新的关键信息，这导致了新的新信息 然后可以在基本实验室中审问的假设。因此，免疫学和 癌症计划已演变为一个明确的双向翻译研究例子。